Experimental Ebola drugs enter the limelight

The phase 1 drug hit a roadblock earlier in the summer when it raised cytokine levels in healthy volunteers, but has since been cleared by the US Food and Drug Administration for use in infected patients. The US National Institutes of Health (NIH) and GlaxoSmithKline are developing a second vaccine,...

Full description

Saved in:

Bibliographic Details
Published in:	The Lancet (British edition) 2014-08, Vol.384 (9944), p.649-649
Main Author:	Mullard, Asher
Format:	Article
Language:	eng
Subjects:	Africa - epidemiology Animals Antibodies, Monoclonal - pharmacology Antiviral Agents - pharmacology Drug dosages Drugs, Investigational - pharmacology Ebola virus Hemorrhagic Fever, Ebola - drug therapy Hemorrhagic Fever, Ebola - epidemiology Humans Infections Internal Medicine Medical research Public health RNA, Small Interfering - pharmacology Vaccines Viral Vaccines - pharmacology World Health Organization
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The phase 1 drug hit a roadblock earlier in the summer when it raised cytokine levels in healthy volunteers, but has since been cleared by the US Food and Drug Administration for use in infected patients. The US National Institutes of Health (NIH) and GlaxoSmithKline are developing a second vaccine, a recombinant chimp adenovirus that expresses the glycoproteins of two different strains of Ebola virus.
ISSN:	0140-6736 1474-547X